



AHCL/ SE/31/2025-26

November 10, 2025

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
<b>Symbol: AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **November 10, 2025** had inter-alia:

- (i) Approved the Unaudited Financial Results for the quarter and half year ended September 30, 2025, as recommended by the Audit Committee at its meeting held on November 10, 2025. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared First Interim Dividend of Re.1/- per share for the financial year 2025-26 on the Equity Shares of the Company.

The Board Meeting commenced at 12:00 P.M and concluded at 4.30 P.M.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

**(Gagan Preet Singh )**  
**General Manager- Legal**  
**Company Secretary-cum-Compliance Officer**

**Encl:**

1. Un-audited Standalone Financials Results for the quarter and half year ended September 30, 2025
2. Limited Review Report

**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Statement of Unaudited Financial Results for the quarter and half year ended 30 September 2025**

							(Amount in INR Lakhs)
	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2025 (Unaudited)	30 June 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
I	Revenue from operations	11,770.02	9,404.57	10,991.52	21,174.59	19,365.12	45,181.63
II	Other income	429.63	442.74	404.71	872.37	849.91	1,767.87
III	Total income (I + II)	12,199.65	9,847.31	11,396.23	22,046.96	20,215.03	46,949.50
IV	Expenses						
	(a) Cost of materials consumed	2,512.38	2,123.63	1,815.82	4,636.01	3,966.80	10,059.69
	(b) Purchase of stock-in-trade	3,519.07	3,116.27	3,448.44	6,635.34	6,179.30	12,317.94
	(c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(265.95)	(300.88)	176.44	(566.83)	(304.67)	(56.90)
	(d) Employee benefits expense	1,595.08	1,601.31	1,452.33	3,196.39	2,838.27	5,910.27
	(e) Finance cost	4.97	5.15	5.54	10.12	12.00	21.92
	(f) Depreciation and amortisation expense	155.77	153.07	165.27	308.84	324.00	652.61
	(g) Other expenses						
	- Advertisement and selling expenditure	1,374.95	736.94	1,490.37	2,111.89	2,367.15	5,611.04
	- Others	1,381.89	1,282.55	1,247.99	2,664.44	2,603.27	5,519.53
	Total expenses (IV)	10,278.16	8,718.04	9,802.20	18,996.20	17,986.12	40,036.10
V	Profit before tax (III - IV)	1,921.49	1,129.27	1,594.03	3,050.76	2,228.91	6,913.40
VI	Tax expenses	525.33	298.15	414.47	823.48	587.79	1,829.93
VII	Profit after tax (V - VI)	1,396.16	831.12	1,179.56	2,227.28	1,641.12	5,083.47
VIII	Other comprehensive income / (loss)						
	Items that will not be reclassified subsequently to profit or loss						
	Re-measurement gain/(loss) on defined benefit plans	(26.08)	(7.52)	(39.90)	(33.60)	(43.84)	(105.87)
	Income tax relating to items that will not be reclassified to profit or loss	6.57	1.89	10.04	8.46	11.03	26.65
	Other comprehensive income/ (loss), net of taxes	(19.51)	(5.63)	(29.86)	(25.14)	(32.81)	(79.22)
IX	Total comprehensive income (VII + VIII)	1,376.65	825.49	1,149.70	2,202.14	1,608.31	5,004.25
	Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11	289.11
	Other equity						32,372.35
	Earnings per equity share						
	Basic earnings per share (INR)	4.83	2.87	4.08	7.70	5.68	17.58
	Diluted earnings per share (INR)	4.83	2.87	4.08	7.70	5.68	17.58
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	See accompanying notes to Unaudited financial results						



**Note 1: Statement of assets and liabilities**

(Amount in INR in Lakhs)

S. No.	Particulars	As at 30 September 2025	As at 31 March 2025
		(Unaudited)	(Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	4,542.60	4,584.52
	(b) Right-of-use assets	169.55	188.28
	(c) Capital work in progress	2,640.78	1,619.78
	(d) Intangible assets	177.00	167.81
	(e) Intangible assets under development	13.70	5.00
	(f) Financial assets		
	Investments	4.33	4.51
	Other financial assets	3,387.97	4,165.29
	(g) Deferred tax assets (net)	328.88	311.17
	(h) Other tax assets (net)	302.10	260.05
	(i) Other non-current assets	2,452.31	1,765.37
	<b>Total non-current assets</b>	<b>14,019.22</b>	<b>13,071.78</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	3,550.11	2,725.98
	(b) Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	3,830.40	5,582.18
	(iii) Cash and cash equivalents	515.22	1,015.52
	(iv) Bank balances other than (iii) above	5,796.38	7,300.10
	(v) Other financial assets	14,434.69	11,617.07
	(c) Other current assets	1,089.80	826.15
	<b>Total current assets</b>	<b>29,216.60</b>	<b>29,067.00</b>
	<b>Total assets (1+2)</b>	<b>43,235.82</b>	<b>42,138.78</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity share capital	289.11	289.11
	(b) Other equity	33,917.66	32,372.35
	<b>Total equity</b>	<b>34,206.77</b>	<b>32,661.46</b>
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	163.60	167.63
	Other financial liabilities	21.50	21.50
	(b) Provisions	917.54	829.89
	<b>Total non-current liabilities</b>	<b>1,102.64</b>	<b>1,019.02</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	29.65	40.18
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	327.18	193.97
	total outstanding dues of creditors other than micro enterprises and small enterprises	5,473.17	6,710.30
	Other financial liabilities	947.06	168.44
	(b) Other current liabilities	728.39	944.57
	(c) Provisions	253.77	233.65
	(d) Current tax liabilities (net)	167.19	167.19
	<b>Total current liabilities</b>	<b>7,926.41</b>	<b>8,458.30</b>
	<b>Total liabilities (2+3)</b>	<b>9,029.05</b>	<b>9,477.32</b>
	<b>Total equity and liabilities (1+2+3)</b>	<b>43,235.82</b>	<b>42,138.78</b>



**Note 2: Statement of Cash flows**

Particulars	(Amount in INR in Lakhs)		
	For the half year ended 30 September 2025	For the half year ended 30 September 2024	For the year ended 31 March 2025
	(Unaudited)	(Unaudited)	(Audited)
<b>Cash flow from operating activities</b>			
Profit before tax	3,050.76	2,228.91	6,913.40
Adjustments for:			
Depreciation and amortisation expense	308.84	324.00	652.61
Profit on sale of property, plant and equipment	(10.38)	-	-
Equity-settled share-based payment transactions	87.88	50.16	114.50
Loss allowance on trade receivables	43.20	109.37	25.97
Bad debts written off	0.15	0.42	0.42
Change in fair value of financial assets at FVTPL	0.18	(1.25)	(0.20)
Interest income on cash and cash equivalents and other bank balances	(738.26)	(701.86)	(1,446.57)
Interest income on corporate debt securities and loans at amortised cost	(79.15)	(78.53)	(158.15)
Interest income on debt instruments	-	-	(0.02)
Excess provision written back, net	(21.22)	(58.78)	(143.69)
Finance costs	10.12	11.09	21.92
<b>Operating profit before working capital / other changes</b>	<b>2,652.12</b>	<b>1,883.53</b>	<b>5,980.19</b>
<b>Working capital adjustments:</b>			
Decrease/ (Increase) in trade receivables	1,708.45	1,215.74	(819.63)
(Increase) in other current and non-current assets	(266.19)	(147.80)	(83.78)
(Increase) in other financial assets	(11.29)	(4.20)	(2.35)
(Increase)/ Decrease in inventories	(824.13)	(372.80)	164.49
(Decrease)/ Increase in other current/non-current financial liabilities	(68.75)	(59.10)	12.65
Increase in provisions	74.17	25.45	64.69
(Decrease)/ Increase in trade payables	(1,082.70)	(192.46)	1,461.70
(Decrease)/ Increase in other current liabilities	(216.18)	89.97	104.21
	<b>(686.62)</b>	<b>554.80</b>	<b>901.98</b>
<b>Cash generated from operating activities</b>	<b>1,965.50</b>	<b>2,438.33</b>	<b>6,882.17</b>
Less: Income tax paid (net)	(874.78)	(816.13)	(1,792.25)
<b>Net cash generated from operating activities (a)</b>	<b>1,090.72</b>	<b>1,622.20</b>	<b>5,089.92</b>
<b>Cash flows from investing activities</b>			
Purchase or construction of property, plant and equipment, intangible assets, capital work-in progress, intangible assets under development, movement in capital advances and payable towards purchase of property, plant and equipment	(1,872.88)	(359.78)	(3,555.29)
Proceeds from sale of Property, plant and equipment	10.38	-	-
Redemption/ (Investment) in bank deposits and financial institutions	486.29	(722.07)	(1,146.16)
Interest received on deposits with banks and financial institutions, net	554.60	545.91	1,604.74
Proceeds from redemption of investments	-	0.01	0.05
Interest received on debt instruments	-	-	0.02
<b>Net cash (used in) / generated from investing activities (b)</b>	<b>(821.61)</b>	<b>(535.93)</b>	<b>(3,096.64)</b>
<b>Cash flow from financing activities</b>			
Dividend paid	(751.68)	(751.68)	(1,326.65)
Sale of shares by employee stock option trust	6.95	23.20	23.78
Payment of lease liabilities	(24.68)	(21.65)	(46.09)
<b>Net cash (used in) / generated from financing activities (c)</b>	<b>(769.41)</b>	<b>(750.13)</b>	<b>(1,348.96)</b>
<b>Net change in cash and cash equivalents (a) + (b) + (c)</b>	<b>(500.30)</b>	<b>336.14</b>	<b>644.32</b>
Cash and cash equivalents at the beginning of the year / period	1,015.52	371.20	371.20
Effect of exchange rate fluctuations on cash held	-	-	-
<b>Cash and cash equivalents at the end of the year / period</b>	<b>515.22</b>	<b>707.34</b>	<b>1,015.52</b>
<b>Components of cash and cash equivalents</b>			
Cash on hand	4.87	5.43	3.70
Bank balances	510.35	701.91	1,011.82
<b>Cash and cash equivalents as per Statement of assets and liabilities</b>	<b>515.22</b>	<b>707.34</b>	<b>1,015.52</b>

**Note:** The above cash flow statement has been prepared under the "indirect method" as set out in the Ind AS 7 on statement of Cash Flows specified under section 133 of the Companies Act, 2013.





**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Notes:**

3. The above unaudited financial results for the quarter and half year ended 30 September 2025 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 10 November 2025. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.

4. These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5. The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.

6. The shareholders of the Company at its Annual General Meeting held on 23 September 2025, has approved final dividend of INR 2.60/- per equity share of face value INR 1/- each for the financial year ended 31 March 2025.

7. During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024.

8. During the financial year 2005-06, the Government of Tamil Nadu retrospectively revised the lease rent for a leasehold land, effective from November 2001, by determining fair rent under Section 34A of the Tamil Nadu Hindu Religious and Charitable Endowments Act, 1959. Pursuant to this revision, a demand notice was issued to the Company. Accordingly, the Company had filed a Writ Petition before the High Court of Judicature, Madras challenging the fair rent determination, contending that the revision was exorbitant and not legally tenable. On 25 September 2025, the High Court of Judicature, Madras has dismissed the petition and upheld the rent fixed by the Fair Rent Committee constituted by the Government of Tamil Nadu. Based on the advice from the external consultant, the Company is in the process of filing an appeal before the Division Bench of the High Court of Judicature, Madras and hence no adjustments have been considered in the unaudited financial results.

9. The unaudited financial results of the Company for the quarter and half year ended 30 September 2025 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.

10. **Segment reporting in the Unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segment (represents Pain Management Centre).

Particulars		Quarter ended			Half year ended		(Amount in INR Lakhs)
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31 March 2025
1	Segment revenue						
a	OTC Products	8,001.84	5,697.24	7,325.82	13,699.08	11,931.31	29,002.99
b	Women's Hygiene	3,278.04	2,860.75	3,300.10	6,138.79	5,958.11	12,396.25
c	Beverages	428.84	776.01	338.86	1,204.85	1,434.37	3,643.01
d	Others	61.30	70.57	26.74	131.87	41.33	139.38
	<b>Total</b>	<b>11,770.02</b>	<b>9,404.57</b>	<b>10,991.52</b>	<b>21,174.59</b>	<b>19,365.12</b>	<b>45,181.63</b>
2	Segment results						
a	OTC Products	1,841.04	1,079.14	1,571.96	2,920.18	2,134.96	6,557.17
b	Women's Hygiene	(125.74)	14.85	(145.46)	(110.89)	(166.68)	(391.05)
c	Beverages	(64.87)	(299.82)	(124.64)	(364.69)	(249.70)	(243.56)
d	Others	(15.10)	(4.51)	(13.19)	(19.61)	(42.24)	(81.43)
	<b>Total</b>	<b>1,635.33</b>	<b>789.66</b>	<b>1,288.67</b>	<b>2,424.99</b>	<b>1,676.34</b>	<b>5,841.13</b>
	Less: Finance cost	4.97	5.15	5.54	10.12	12.00	21.92
	Add: Interest income net of other unallocable expenditure	291.13	344.76	310.90	635.89	564.57	1,094.19
	<b>Total profit before tax</b>	<b>1,921.49</b>	<b>1,129.27</b>	<b>1,594.03</b>	<b>3,050.76</b>	<b>2,228.91</b>	<b>6,913.40</b>
3	Segment assets						
a	OTC Products	7,027.96	6,769.06	6,528.80	7,027.96	6,528.80	6,800.73
b	Women's Hygiene	6,877.07	5,707.88	2,195.38	6,877.07	2,195.38	5,209.00
c	Beverages	2,566.63	2,736.46	2,416.69	2,566.63	2,416.69	3,503.26
d	Others	126.35	125.54	119.43	126.35	119.43	122.13
e	Unallocated assets	26,637.81	26,562.01	26,999.20	26,637.81	26,999.20	26,503.68
	<b>Total</b>	<b>43,235.82</b>	<b>41,900.95</b>	<b>38,259.50</b>	<b>43,235.82</b>	<b>38,259.50</b>	<b>42,138.80</b>
4	Segment liabilities						
a	OTC Products	5,190.02	5,084.47	5,309.99	5,190.02	5,309.99	5,539.80
b	Women's Hygiene	1,673.34	1,289.62	1,206.86	1,673.34	1,206.86	1,646.36
c	Beverages	690.98	1,217.50	425.38	690.98	425.38	1,359.50
d	Others	65.64	52.18	48.80	65.64	48.80	42.67
e	Unallocated liabilities	1,409.07	726.28	1,489.65	1,409.07	1,489.65	889.01
	<b>Total</b>	<b>9,029.05</b>	<b>8,370.05</b>	<b>8,480.68</b>	<b>9,029.05</b>	<b>8,480.68</b>	<b>9,477.34</b>
	<b>Total capital employed in the Company</b>	<b>34,206.77</b>	<b>33,530.90</b>	<b>29,778.82</b>	<b>34,206.77</b>	<b>29,778.82</b>	<b>32,661.46</b>

For Amrutanjan Health Care Limited

  
**S Sambhu Prasad**  
Chairman & Managing Director  
DIN: 00015729

# BSR & Co. LLP

Chartered Accountants

KRM Tower, 1st and 2nd Floors  
No. 1, Harrington Road, Chetpet  
Chennai – 600 031, India  
Telephone: +91 44 4608 3100  
Fax: +91 44 4608 3199

## Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 30 September 2025 and year to date results for the period from 1 April 2025 to 30 September 2025 ("the Statement") in which are included the unaudited financial results of Amrutanjan Health Care Limited ESOP trust ("ESOP trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BSR & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022

**R Kalyana Sundara Rajan**

Partner

Chennai

10 November 2025

Membership No.: 221822

UDIN: 25221822BMMKEL3101